HomeCompareNMRD vs ORCC

NMRD vs ORCC: Dividend Comparison 2026

NMRD yields 1000000.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMRD wins by $4.7683925249533696e+36M in total portfolio value
10 years
NMRD
NMRD
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full NMRD calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — NMRD vs ORCC

📍 NMRD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMRDORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMRD + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMRD pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMRD
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, NMRD beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMRD + ORCC for your $10,000?

NMRD: 50%ORCC: 50%
100% ORCC50/50100% NMRD
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

NMRD
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-23.5
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMRD buys
0
ORCC buys
0
PoliticianChamberTickerTypeAmountDate
Dianne Feinstein🏛 Senate$NMRD▼ Sell$15,001 - $50,0002022-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMRDORCC
Forward yield1000000.00%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$4.7683925249533696e+36M$21.4K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$1.04
Total dividends collected$4.7683311610149396e+36M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: NMRD vs ORCC ($10,000, DRIP)

YearNMRD PortfolioNMRD Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,190$489.61+$100.00MNMRD
2$934,786,450,701$934,679,439,252.34$12,229$256.01+$934786.44MNMRD
3$8,165,787,108,578,292$8,164,786,887,076,042.00$13,216$130.74+$8165787108.57MNMRD
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$14,207$66.02+$66665884190957.63MNMRD
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$15,234$33.17+$508662171058048128.00MNMRD
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,317$16.62+$3.62723524842849e+21MNMRD
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$17,468$8.32+$2.417368115915061e+25MNMRD
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$18,695$4.16+$1.5056740286145463e+29MNMRD
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$20,006$2.08+$8.764771002818475e+32MNMRD
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$21,407$1.04+$4.7683925249533696e+36MNMRD

NMRD vs ORCC: Complete Analysis 2026

NMRDStock

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Full NMRD Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this NMRD vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMRD vs SCHDNMRD vs JEPINMRD vs ONMRD vs KONMRD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.